Igor A. Karpov

Igor A. Karpov

Auto-generated profile, based on publicly available information

Igor A. Karpov

Belarusian State Medical University

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2007 in Vaccine
Verified
Journal Article
Closed access
AAAlena V. Atrasheuskaya
Alena V. Atrasheuskaya
EBElena M. Blatun
Elena M. Blatun
MKMichail V. Kulak
Michail V. Kulak
AAAlina Atrasheuskaya
Alina Atrasheuskaya
IKIgor A. Karpov
Igor A. Karpov
GIGeorge M. Ignatyev
George M. Ignatyev

31 January 2011 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
WBWendy P. Bannister
Wendy P. Bannister
JKJ. Kjaer
J. Kjaer
APA. Phillips
A. Phillips
OGon behalf of the EuroSIDA group
on behalf of the EuroSIDA group
MLM. Losso
M. Losso
JKJesper KjæR
Jesper KjæR
Estimating the prevalence of accumulated HIV drug resistance in patients receiving antiretroviral therapy (ART) is difficult due to lack of resistance testing at all occasions of virological failure and in patients with undetectable viral load. A method to estimate this for 6498 EuroSIDA patients who were under follow-up on ART at 1 July 2008 was therefore developed by imputing data on patients with no prior resistance test results, based on the probability of detecting resistance in tested patients with similar profiles. Using all resistance test results available, predicted intermediate/high-level resistance to specific drug classes [nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs)] was derived using the Stanford algorithm v5.1.2. Logistic regression models were then employed to estimate predicted probability of resistance to each drug class for given values of current viral load, history of virological failure and previous virological suppression. Based on these predicted probabilities and patients’ covariate profiles, estimates of prevalence in 5355 patients with no prior test results were obtained. Overall prevalence of resistance was estimated by pooling these data with those observed in the remaining 1143 tested patients. Prevalence of NRTI, NNRTI and PI resistance was estimated as 43% (95% confidence interval: 39%–46%), 15% (13%–18%) and 25% (22%–28%), respectively. This method provides estimates for the proportion of treated patients in a cohort who harbour resistance on a given date, which are less likely to be affected by selection bias due to missing resistance data and will allow us to estimate prevalence of resistance to different drug classes at specific timepoints in HIV-infected populations on ART.

23 May 2021 in Russian Clinical Laboratory Diagnostics
Verified
Journal Article
Open access
DTD. V. Tapalski
D. V. Tapalski
ETE. V. Timoshkova
E. V. Timoshkova
TPT. A. Petrovskaya
T. A. Petrovskaya
OOO. V. Osipkina
O. V. Osipkina
IKI. A. Karpov
I. A. Karpov
Combined antibiotic therapy is widely used for infections caused by carbapenem-resistant K. pneumoniae. The objective of this work was to identify the synergistic activity of combinations of two carbapenems against multidrug- and extensively drug-resistant K. pneumoniae strains producing various types of carbapenemases. For 60 antibiotic-resistant K. pneumoniae strains isolated in 8 cities of Belarus, the minimum inhibitory concentrations (MIC) of colistin and carbapenems were determined by subsequent broth microdilution method, and the genes of carbapenemases and phosphoethanolamine transferases were detected. The checkerboard method was used to determine the sensitivity to the combination of ertapenem and doripenem. High MIC values of carbapenems were revealed for NDM carbapenemase-producing strains (MIC50 of meropenem 64 mg/L, MIC50 of doripenem 64 mg/L). Doripenem was more active; MIC of doripenem ≤ 16 mg/L (low level of resistance) was determined in 28 (46.7%) strains, MIC of meropenem ≤ 16 mg/L - in 8 (13.3% of strains). The effect of potentiating the activity of doripenem with ertapenem at a fixed pharmacokinetic / pharmacodynamic concentration was observed for 20.0% of the strains producing KPC carbapenemase and 29.0% of the strains producing OXA-48 carbapenemase. The potentiating effect was independent of the presence of colistin resistance. Thus, the ability of ertapenem to potentiate the antimicrobial activity of doripenem and meropenem against some of the strains producing serine carbapenemases (KPC and OXA-48) was confirmed. The necessity of routine determination of the true MIC values of carbapenems was shown to optimize their dosage regimens and select the combination antibiotic therapy regimens.

1 April 2018 in Immunopathology, Allergology, Infectology
Verified
Journal Article
Closed access
ESE Shek
E Shek
DTD Tapalski
D Tapalski
ESE Skleenova
E Skleenova
MSM Sukhorukova
M Sukhorukova
IKI Karpov
I Karpov
MEMikhail V. Edelstein
Mikhail V. Edelstein

12 April 2021 in Клиническая инфектология и паразитология
Verified
Journal Article
Closed access
ИКИ.а. Карпов
И.а. Карпов
Издание посвящено вопросам своевременной диагностики и лечения вирусных, инфекционных и паразитических заболеваний различного генеза.

20 October 2026
Verified
Journal Article
Open access
PDF file
DLD. Litvinchuk
D. Litvinchuk
DDD. Danilau
D. Danilau
IKI. Karpov
I. Karpov
ДЛД. В. Литвинчук
Д. В. Литвинчук
ДДД. Е. Данилов
Д. Е. Данилов
ИКИ. А. Карпов
И. А. Карпов
Objective. To characterize clinical severity of COVID-19 in hospitalized patients during pandemic periods and to assess the effect of vaccination on disease course. Materials and methods. Single-centre retrospective cohort study of 11,203 patients hospitalized with COVID-19 in 2020– 2023 (112,455 bed-days). Clinical severity was graded on a four-level respiratory failure scale: «none»; «oxygen mask/cannula»; «noninvasive ventilation» (NIV); «invasive mechanical ventilation» (IMV). Bayesian hierarchical ordinal regression was fitted with covariates: age, Elixhauser comorbidity index, vaccination, previous-day respiratory failure, pandemic day and disease days. Statistical analysis was performed with programming languages R 4.6.0 and Stan 2.38.0. Results. The 28-day cumulative risk of respiratory failure was up to 50 % in the first wave, up to 80 % in the period of Alpha variant predominance, > 90 % (unvaccinated) and ≤ 65 % (vaccinated) in the period of Delta variant predominance, and ≤ 25 % in the Omicron. During predominance of Delta variant, the probability of NIV/IMV reached 25–30 % in older unvaccinated patients with comorbidities compared to ≤ 4.5 % in vaccinated ones; during predominance of Omicron variants it was < 1 %, though up to 20 % still required oxygen. After standardization, vaccination was associated with a lower cumulative risk from September 2021 to March 2022, peaking in December 2021: -24.3 % (95 % CI (-17,6; -30,6)). Conclusion. Respiratory failure severity varied by pandemic period, and vaccination against SARS-CoV-2 had a protective effect in hospitalized patients.